Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy

Hsin Ming Chen; Chin Tin Chen; Hsiang Yang; Mark Yen Ping Kuo; Ying Shiung Kuo; Wan Hong Lan; Yi Ping Wang; Tsuimin Tsai; Chun Pin Chiang

doi:10.1016/j.oraloncology.2003.12.010

Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy

Hsin Ming Chen, Chin Tin Chen, Hsiang Yang, Mark Yen Ping Kuo, Ying Shiung Kuo, Wan Hong Lan, Yi Ping Wang, Tsuimin Tsai, Chun Pin Chiang

Graduate Institute of Biomedical Materials and Tissue Engineering

Research output: Contribution to journal › Article › peer-review

77 Citations (Scopus)

Abstract

Previous studies have shown a selective accumulation of 5-aminolevulinic acid (ALA)-derived protoporphrin IX (PpIX) in oral premalignant and malignant tissues. This provides a biologic rationale for the clinical use of ALA-mediated PDT (ALA-PDT) for oral premalignant and malignant lesions. In this study, five patients with oral verrucous hyperplasia (OVH) were treated with a new protocol of ALA-PDT composed of multiple 3-min irradiations with a light emitting diode (LED) red light at 635±5 nm separated with several 3-min rests for a total of 1000 s (fluence rate, 100 mW/cm²; light exposure dose, 100 J/cm²) after topical application of 20% ALA for 1.5 or 2 h. Topical ALA-PDT was repeated once a week until the complete regression of the lesion. Complete regression of all OVH lesions was observed after 1-3 treatments (average, 2 treatments) of topical ALA-PDT. At an average follow-up of 5.6 months (range, 3-11 months), all the five OVH patients were free of tumor recurrence. We conclude that topical ALA-PDT with fractionated irradiations by an LED red light at 635±5 nm is an effective and successful treatment modality for OVH.

Original language	English
Pages (from-to)	630-637
Number of pages	8
Journal	Oral Oncology
Volume	40
Issue number	6
DOIs	https://doi.org/10.1016/j.oraloncology.2003.12.010
Publication status	Published - Jul 2004

Keywords

5-aminolevulinic acid
Oral verrucous hyperplasia
Photodynamic therapy

ASJC Scopus subject areas

Oral Surgery
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oraloncology.2003.12.010

Cite this

@article{2f1a1ad1f4a942deb3e60b388e21d8d9,

title = "Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy",

abstract = "Previous studies have shown a selective accumulation of 5-aminolevulinic acid (ALA)-derived protoporphrin IX (PpIX) in oral premalignant and malignant tissues. This provides a biologic rationale for the clinical use of ALA-mediated PDT (ALA-PDT) for oral premalignant and malignant lesions. In this study, five patients with oral verrucous hyperplasia (OVH) were treated with a new protocol of ALA-PDT composed of multiple 3-min irradiations with a light emitting diode (LED) red light at 635±5 nm separated with several 3-min rests for a total of 1000 s (fluence rate, 100 mW/cm2; light exposure dose, 100 J/cm2) after topical application of 20% ALA for 1.5 or 2 h. Topical ALA-PDT was repeated once a week until the complete regression of the lesion. Complete regression of all OVH lesions was observed after 1-3 treatments (average, 2 treatments) of topical ALA-PDT. At an average follow-up of 5.6 months (range, 3-11 months), all the five OVH patients were free of tumor recurrence. We conclude that topical ALA-PDT with fractionated irradiations by an LED red light at 635±5 nm is an effective and successful treatment modality for OVH.",

keywords = "5-aminolevulinic acid, Oral verrucous hyperplasia, Photodynamic therapy",

author = "Chen, {Hsin Ming} and Chen, {Chin Tin} and Hsiang Yang and Kuo, {Mark Yen Ping} and Kuo, {Ying Shiung} and Lan, {Wan Hong} and Wang, {Yi Ping} and Tsuimin Tsai and Chiang, {Chun Pin}",

note = "Funding Information: This study was supported by research grants of NSC90-2736-L-002-002 and NSC90-2736-L-002-003 from the National Science Council, Taipei, Taiwan.",

year = "2004",

month = jul,

doi = "10.1016/j.oraloncology.2003.12.010",

language = "English",

volume = "40",

pages = "630--637",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy

AU - Chen, Hsin Ming

AU - Chen, Chin Tin

AU - Yang, Hsiang

AU - Kuo, Mark Yen Ping

AU - Kuo, Ying Shiung

AU - Lan, Wan Hong

AU - Wang, Yi Ping

AU - Tsai, Tsuimin

AU - Chiang, Chun Pin

N1 - Funding Information: This study was supported by research grants of NSC90-2736-L-002-002 and NSC90-2736-L-002-003 from the National Science Council, Taipei, Taiwan.

PY - 2004/7

Y1 - 2004/7

N2 - Previous studies have shown a selective accumulation of 5-aminolevulinic acid (ALA)-derived protoporphrin IX (PpIX) in oral premalignant and malignant tissues. This provides a biologic rationale for the clinical use of ALA-mediated PDT (ALA-PDT) for oral premalignant and malignant lesions. In this study, five patients with oral verrucous hyperplasia (OVH) were treated with a new protocol of ALA-PDT composed of multiple 3-min irradiations with a light emitting diode (LED) red light at 635±5 nm separated with several 3-min rests for a total of 1000 s (fluence rate, 100 mW/cm2; light exposure dose, 100 J/cm2) after topical application of 20% ALA for 1.5 or 2 h. Topical ALA-PDT was repeated once a week until the complete regression of the lesion. Complete regression of all OVH lesions was observed after 1-3 treatments (average, 2 treatments) of topical ALA-PDT. At an average follow-up of 5.6 months (range, 3-11 months), all the five OVH patients were free of tumor recurrence. We conclude that topical ALA-PDT with fractionated irradiations by an LED red light at 635±5 nm is an effective and successful treatment modality for OVH.

AB - Previous studies have shown a selective accumulation of 5-aminolevulinic acid (ALA)-derived protoporphrin IX (PpIX) in oral premalignant and malignant tissues. This provides a biologic rationale for the clinical use of ALA-mediated PDT (ALA-PDT) for oral premalignant and malignant lesions. In this study, five patients with oral verrucous hyperplasia (OVH) were treated with a new protocol of ALA-PDT composed of multiple 3-min irradiations with a light emitting diode (LED) red light at 635±5 nm separated with several 3-min rests for a total of 1000 s (fluence rate, 100 mW/cm2; light exposure dose, 100 J/cm2) after topical application of 20% ALA for 1.5 or 2 h. Topical ALA-PDT was repeated once a week until the complete regression of the lesion. Complete regression of all OVH lesions was observed after 1-3 treatments (average, 2 treatments) of topical ALA-PDT. At an average follow-up of 5.6 months (range, 3-11 months), all the five OVH patients were free of tumor recurrence. We conclude that topical ALA-PDT with fractionated irradiations by an LED red light at 635±5 nm is an effective and successful treatment modality for OVH.

KW - 5-aminolevulinic acid

KW - Oral verrucous hyperplasia

KW - Photodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=1842424985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842424985&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2003.12.010

DO - 10.1016/j.oraloncology.2003.12.010

M3 - Article

C2 - 15063392

AN - SCOPUS:1842424985

SN - 1368-8375

VL - 40

SP - 630

EP - 637

JO - Oral Oncology

JF - Oral Oncology

IS - 6

ER -

Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this